Does innovation lead to patents, or patents lead to innovation?

By Gene Quinn
April 20, 2017

I recently had the opportunity to speak on the record with Matt Levy, current counsel with Wiley Rein and former patent counsel for the Computer & Communications Industry Association. To start reading our conversation from the beginning please see A Software Patent Discussion with Matt Levy. What follows is part 2 of our interview; the final segment. We pick up our conversation with me suggesting that there is a problem with claims being found to be abstract when the decision maker has been able to do a complete 102 (novelty) and 103 (obviousness) analysis. We then move on to discuss the meaning of “innovation,” whether innovation leads to patents or patents lead to innovation, and briefly touch on a long-time disagreement about whether patents are property rights.

______________

QUINN: I understand what you’re saying but I still have a problem and maybe it’s because fundamentally what I would say and how I would like to see the abstract idea exception implemented is that if you can do a 102 and if you can do a 103 then I would say that you have satisfied the minimum threshold of 101, which had always been the very lowest threshold. And if there are any problems they should be considered under 112. Because it seems to me that if it is concrete enough to evaluate the prior art that the examiner raised it can’t be abstract.

LEVY: That’s not necessarily the meaning of abstract in this context though.

QUINN: Well, and that’s again the problem. We don’t have a definition. So whoever is the decision maker gets to use their own definition, which I think is a real big problem.

LEVY: Well, that’s why I actually like what the Federal Circuit has been doing in the last year or so which is saying, okay, look, we’ve got this abstract idea, but we need to come up with something more practical. And so what they did is they flipped it around and basically they’re looking now to whether — they’re not looking to see whether there’s just conventional stuff, they’re looking to see whether there is something technical here that would improve the performance of the device. And I think that that’s fundamentally a good question to be asking, because that’s really what we’re trying to get at, right? It may seem like oh that’s the same thing but it’s not. If you’re actively looking to find the technical improvement that’s not the same thing as just framing it as well it’s a bunch of stuff and then this other stuff is conventional so there’s nothing new here. I think the way that you frame actually is important. I think that there’s a lot of physiological evidence for this, although I’m certainly no expert on that. Framing it as, “Let’s look to see if there are technical improvements,” is a good way to go and I think that’s why we now have more decisions like Enfish and McRo where the court is saying, well, look we can find it here. And I’m hoping that if we follow this approach and let it evolve some more, this will ease some of the pain that I know a lot of what you’re calling pro patent people feel. When you’re actively looking for the innovation instead of trying to find a way to not find the innovation it’s a bit different. You see what I’m saying?

QUINN: Yeah.

LEVY: I don’t know if that — I mean,, I think just if we — because that’s really what we should be doing, right? We should be looking to see what is the innovation that they’re trying to claim, and if we can’t find a technical thing here when we look for it then that’s a problem.

QUINN: Yeah. It is. Okay. So we kind of got far afield from where we originally started this and I don’t think we really wrapped it up because I didn’t even get out the Lincoln quote, you know “the fire of genius” quote. Because that to me I think is fundamental when you’re considering whether or not patents drive innovation or patents follow innovation. And to me I think in some cases when you’re talking about incremental innovation and you’re talking about large entities patents probably follow innovation. And I think when you’re talking about independent inventors, startup companies, and even large entities like maybe an IBM particularly when they’re dealing with a real speculative research budget, the type of budget that would lead to Watson, for example, I think patents drive it because without the patent you could never begin to go down that path and invest that kind of money to bring it into being, it just wouldn’t be worthwhile.

LEVY: Well, so maybe what we have here is a definitional problem, which is “innovation.” When does something become an innovation, how early? When is it still just sort of this nascent idea and when does it actually cross the line into becoming innovation? If that happens earlier, then patents definitely come afterwards because those initial steps, the inspiration for Watson had nothing to do with patents. But I think you’re right that they would never have spent the however many hundreds of millions they spent on that thing if there were no patents. So when, where is the innovation? Is it in the completed product? Is it earlier? I suspect that there isn’t one, of course there’s not one, innovation, there are thousands of innovations that go into something that complicated. So the initial ones happen, I think is my theory, happen whether they’re patents or not. And then in order to move forward you do need some kind of intellectual property protection like patents because otherwise you’re just not going to invest that kind of money. Then of course as you develop the product, further innovations are developed because that’s part of making a final product especially in the computer space. And then those probably also come with patents, so the patents that led you to protect the thing and go forward with development arguably drove the innovations, the build-on innovations that came later as you were developing the product further. Does that make sense?

QUINN: Yeah, yeah.

LEVY: It sort of goes back and forth.

QUINN: Yeah.

LEVY: Right. Except I think that at least the initial innovations come first. Nobody says in my mind nobody says, hey, you know, patents gave me this — because I can get a patent I have this great idea for a thing. The idea for the thing is there’s a problem that needs to be solved. Somebody comes up with a solution for the problem. That’s where the innovations come in. The patents are what lead them to actually develop it further and do something with it rather than just keep it in their head or making it for a few friends or something.

QUINN: Yes and no. And I suppose this is again where you run into problems because of the complexity of the patent system and what motivates people. I think for companies that are research and development companies that innovate if there were no patents those companies wouldn’t exist and they wouldn’t be looking for the solutions to the problems because you couldn’t protect it and monetize it so there would be no reason to invest in looking for solutions to problems.

LEVY: Well, but that’s after they’ve always established the business model. So I think when they started they were looking for solutions to problems. I mean, that’s why they wanted to form a business in the first place. And patents enabled them to follow this business model. But they still were, I mean, I was in academia for a while so I did do that other side. Part of being a PhD student is looking for a problem, and once you’ve found a problem you try and find a solution to it. It’s only after you think you’ve got a solution that you start thinking about patenting or any of that other stuff. Now once you’ve got an R&D company that’s already doing it well, yeah, then the fact that patents are available allows them to follow that business model of just being an R&D company and not having to make products. But I don’t think it was patents that started them on the path to innovation, again at some point it become — ideally it becomes a virtuous circle. Or virtuous cycle.

QUINN: Right.

LEVY: Where the innovation caused them to develop something which then caused them to, you know, they want to get patents, which then leads to more stuff and on and on.

QUINN: Yeah.

LEVY: So if it works it’s a great thing.

QUINN: Yeah. And that’s the problem I think we have right now. I think to a large extent the patent system isn’t working, it’s not providing the incentives that it needs to provide and it’s creating too much risk. I think that there are other countries where you can get better protection and I think people are going to start to locate there and that really worries me because fundamentally the reason that the biotechnology industry in the United States is because of Diamond v. Chakrabarty. The biotech industry didn’t really exist prior to that, and today for many biotech related inventions you can get better protection outside the U.S. Much better protection in some cases.

LEVY: Well, that’s unfortunately out of my area so I’m not really qualified to talk too much about biotech. But I will say this: I think we both agree that patent law right now is definitely in a state of uncertainty and flux. I mean, it’s changing, it’s developing, there’s definitely some discomfort in a lot of sectors. There are some who are very concerned that it’s moving at all.   They want things the way they used to be. There are some who want it to shift. Whatever camp you’re in, things are changing. Whether they will go so far as to drive companies to move, I don’t know. It depends on the industry I guess, and it may be that biotech companies are going to move. Or it may be that they’re just very nervous and they’re expressing that as “We may have to move.” Whether they actually do or not, I don’t know. Clearly there’s a lot of innovation that’s going on in the biotech sector. So to simply throw up your hands and say well those aren’t inventions, that seems kind of disingenuous.

QUINN: Right. There’s certainly innovation that’s going on. The thing that I worry about here is, however you cut it more innovation is going underground, they’re staying underground and being protected as trade secret. I just think that is a negative for society.

LEVY: Well, so here’s an interesting thing. I’m not sure that that’s a bad thing in certain spaces. So I’ll tell you I was talking to some folks in biotech back when the patent reform debate was really hot. I actually went to a BIO conference, because they wanted to hear from the tech sector about why we were pushing for these things. Also, I really wanted to hear from them why they were so terrified of them. It was interesting in the biotech space. It’s extremely competitive and there’s a lot of concern about giving away too much information.

For example, when they sue each other, this is what I was told so I can’t vouch for this personally, the negotiations are very different than what we do in tech. In all the negotiations that I was ever a part of as a litigator you would pretty much lay out your case, both sides would. Lay out why you think that the other side infringes, the other side would lay out the art that they think makes the patent invalid and you have these meetings which were covered by Rule 104 so that they’re negotiations. Everybody pretty much knows, at least at a basic level, what the case is when you’re having real negotiations. In biotech that doesn’t happen at all. They feel like they’re going to reveal some secret about what they do and they just don’t want to do that. Negotiations are much less open than in tech. So there’s I think at least in — let’s just say there are some sectors where there’s a real tension between the public disclosure part of the patent and the protection part and it may be that they really should be using trade secrets rather than patents. So that may not be a bad thing.

QUINN: Yeah. I don’t know.

LEVY: I’d rather have them use trade secrets rather than have them give really an inadequate disclosure and get a patent to protect something. That’s, you know, that’s not right.

QUINN: No.

LEVY: And there should be trade secrets in that case.

QUINN: Yeah. I get that.

LEVY: Because they’re concerned about disclosing.

QUINN: I would prefer that the information would be public so that people can stand on the shoulders of those who’ve come before them. And I understand that some trade secrets are always going to be held. But once upon a time the patent system was a different path, a different choice. And I wonder whether in the minds of some people it’s not a choice anymore; going trade secrets is the only option. And if that is the case, which I think it is, that’s bad. But going back to what you were saying, I think clearly the patent system and patent laws are in a state of flux. And any time you have matters of business and business law that are in a state of flux it creates a certain unease and a climate that is not conducive to growth. Business people don’t want to be risk takers or trendsetters, generally. Sure, great success can be had when you are a risk taker and when you are a trendsetter and that’s why a lot of innovators really succeed, but at the same point in time business thrives when there’s a certainty of the foundational rules and in the patent system right now the most foundational of all rules – what is patent eligible – is in a state of flux and I don’t think that’s good.

LEVY: Well, so here is the thing. Uncertainty, I agree, makes businesses nervous. That’s obvious. But, and again, I’m speaking only for myself here, it seems to me that for many businesses there is a desire to have the benefits of taking the risk without the down side of taking the risk. And one of the downsides here is that the law can change. Patents are not — even if we didn’t change the law — patents are no guarantee of anything. Once you get an issued patent, that patent could be found invalid. It’s in the law that a patent can be challenged and that it can be found invalid. No one should think that once I have this patent that’s it, it’s good for all time and I can take on all comers and they’re going to have to pay me regardless. I have heard too many times people thinking that this is some sort of guarantee and any sort of challenge is a violation of their Constitutional rights. And I’ve heard them say that. And I know you’ve heard it too.

QUINN: I understand that. But where I will agree with them is I think that once you get a property right that the law shouldn’t change retroactively and in the patent space it certainly does. The Supreme Court would never, never do these types of things with retroactive application and legal changes to real property assets.

LEVY: Yeah, but you see I don’t agree that it’s a property right in that sense. It’s something that we treat as a property right but it’s not. You know, the statute says it shall have the aspects of personal property.

QUINN: Yeah. But I do think, and this probably has to be another conversation we’re going to have to have for another day.

LEVY: We can’t do those now. Let’s —

QUINN: I, again, think this is something where we fundamentally disagree, and actually I think we agreed about a year ago to have a conversation on that point.

LEVY: I think we did.

QUINN: So we need to come back to that because it is still a very important issue, and I’m always fascinated when we have these conversations. We do seem to agree on a lot but there are these critical points where we disagree. And I always want to try and figure out where is the point of disagreement. Let’s talk about that and see if there’s any reason that we can come to some kind of commonality or at least common understanding.

LEVY: Yeah, I agree completely. I think that fascinating. And I agree with you. I think that at its core there is some fundamental point where you and I just start from a different place, and then that explains most of the difference if not all the difference.

QUINN: Right.

LEVY: But there’s still a huge overlap in where we basically agree on the purpose of patent law, how it should work.

QUINN: There is, I think. And I know that there are people out there that say just what you said, that any challenge of a patent is unconstitutional. Those are extreme views. Clearly the system has always anticipated and accepted challenges to patents. We can talk about whether that should change to some extent. I thought maybe with the post grant process what we were going to do is get more like the trademark system where if you bring your challenges early you can challenge absolutely anything, you know, full menu. Bring them a little bit later a slightly reduced menu. And then you bring them late then it’s a really reduced menu. But we didn’t go that path. I think maybe we could have that conversation about whether, at some point in time, patent titles should quiet, but Congress didn’t choose to have that conversation in the latest round of patent reform.

LEVY: That’s an interesting point and definitely that’s a deep conversation for another day.

QUINN: Yes. But where I think most people, and me included, get upset is if you told me what the rules were going to be when you’re going to evaluate this invention I can draft the application today to satisfy those rules. Now I’m talking about real innovations and not the type of innovation from Perfect Web, where that which was new was simply resending e-mails. But with a real innovation, if you tell me the standard I can describe it to satisfy that standard. I just think it is fundamentally unfair to have shifting standards applied.

LEVY: Well, so here’s my response to that. Yeah, it’s unfair but that’s life. As lawyers we always face the possibility that the law is going to change.

QUINN: Yes.

LEVY: And that’s just the nature of the business. And if I were going to say — there’s no way to say oh yeah that’s completely fair. No, no, it sucks for the person who just lost a patent that they invested thousands of dollars in. It absolutely sucks and they wouldn’t have written it that way if they’d known what the law was. But we can’t keep the law exactly the same for that reason. If the law is going to change it has to change at some point, and whenever you make that change there are going to be some people on the borderline who unfortunately take it on the chin. And it’s not fair, but it’s life. And it would be nice if everybody could be all happy about everything, but sometimes we get the losing hand; I’ve had it happen to me. It just happens sometimes.

QUINN: No, I hear you. And as much as I’d like to keep going, I’m going to have to end it there. Good news is there’s much more for us to talk about next time. I really appreciate you getting on the phone and having this conversation, Matt, thank you.

LEVY: You know, Gene, I know that people are always surprised when I tell them that you and I get along really well, but I think we need to have more discussions like this, not just you and me but, you know, it’s that ability to find areas of disagreement peacefully that’s really important. Because when people start hyperventilating about “you’re taking away my constitutional property right,” that just shuts down all the discussion and then we can’t get anywhere.

QUINN: I hear you. We have to have these kinds of conversations and hopefully we will more frequently. And I really appreciate the article that you wrote for us a while back and please if you have anything in the future we’d love to have it.

LEVY: Sure. I got some flak for posting on your site but —

QUINN: I bet you did.

LEVY: — I still think it’s good to reach out to that audience. Yeah.

QUINN: All right.

LEVY: All right, Gene, well, thank you so much for giving me the opportunity.

QUINN: No problem. Thanks a lot, Matt, I really appreciate it.

LEVY: All right. I’ll talk to you soon.

UPDATED Thursday, April 20, 2017 at 11:30am ET to fix errors in the transcript.

The Author

Gene Quinn

Gene Quinn is a Patent Attorney and Editor and founder of IPWatchdog.com. Gene is also a principal lecturer in the PLI Patent Bar Review Course and an attorney with Widerman Malek. Gene’s specialty is in the area of strategic patent consulting, patent application drafting and patent prosecution. He consults with attorneys facing peculiar procedural issues at the Patent Office, advises investors and executives on patent law changes and pending litigation matters, and works with start-up businesses throughout the United States and around the world, primarily dealing with software and computer related innovations. is admitted to practice law in New Hampshire, is a Registered Patent Attorney and is also admitted to practice before the United States Court of Appeals for the Federal Circuit. CLICK HERE to send Gene a message.

Warning & Disclaimer: The pages, articles and comments on IPWatchdog.com do not constitute legal advice, nor do they create any attorney-client relationship. The articles published express the personal opinion and views of the author and should not be attributed to the author’s employer, clients or the sponsors of IPWatchdog.com. Read more.

Discuss this

There are currently 22 Comments comments.

  1. Night Writer April 20, 2017 7:41 am

    >>LEVY: I’d rather have them use trade secrets rather than have them give really an inadequate disclosure and get a patent to protect something. That’s, you know, that’s not right.

    Be afraid of trade secrets. Be very afraid. Not until you have worked for a company that bases its IP on trade secrets can you really know how terrible trade secrets can be.

  2. EG April 20, 2017 8:02 am

    To all,

    In the interest of civility and a fair hearing, please, please refrain from personal attacks on Matt. You don’t have to agree with Matt’s views (and I certainly don’t agree with many, if any, of them), but let’s not digress into that “cesspool” that occurs on a different so-called “patent blog.” Again, you can, with civility, attack the issues presented, but please refrain from attacking the person that presents them.

  3. Night Writer April 20, 2017 9:16 am

    What I find strange is all these cognitive models that people put forward about patents and business. They aren’t based on empirical data (or reality).

    The reality is that patents are integrated into the businesses of technology companies. I would like to see an empirically driven discussion of patents. Something that is grounded in reality. I have been a product manager for an international corporation, a software developer at a cutting edge start-up, a patent attorney, a venture capitalist, ect. I have been to MBA school. Computer Science graduate school. Law school. lived in other countries, etc.

    These models that are put forward about patents and innovation just have nothing to do with the reality that I have experienced.

  4. Night Writer April 20, 2017 9:18 am

    And, I think rather than me having to do the work of pointing out the flaws in the models presented above, that Mr. Levy should back up his models with empirical data. I cannot tell you how bizarre I find it that people think they can just generate a fancy about how patents work and tell the world that is how it works.

  5. Pol April 20, 2017 1:14 pm

    Focusing on the biotech aspects of eligibility, whilst the changes caused by Mayo and Myriad have been draconian and a lot of people fall into the ‘borderline’ that Matt talks about, particularly diagnostic companies, I have yet to be convinced that no good will come out of the law changes that have happened. Applicants continue to pursue broad claims, and I think that is hindering the development of that case law at the Federal Circuit level. But the business models and patent strategies being followed by biotech companies will surely adapt. As far as I know no one has empirically worked out the economic cost of overly-broad claiming in the biotech sector. From my personal experience I know university startups are deterred from setting up in areas where there is little freedom to operate. So limiting biotech claims (i.e. excluding the building blocks from patent protection) might lead to a startup explosion in a few year’s time. Once the Federal Circuit has developed the tests for what is a building block and what is genuine innovation in biotech I think the benefits will become clearer. At the moment people are just reacting to the pain they are experiencing and the uncertainty of what the way forward is. Matt appreciates that the law changes and that the Federal Circuit is good at fixing things, and I agree with looking positively at both these things

  6. step back April 20, 2017 1:38 pm

    Trade secrecy is not only anti-innovation, it is anti-science.

    Science requires that the proponent of a new theory/hypothesis lay out all his/her cards on the table so that others can rigorously test it.

    If you say that you have a new data encryption scheme that others cannot crack, with current technology then put it out on the table and let the hackers have a go at it.

    If you say that you have a new cancer treatment protocol that has higher efficacy, then put it out on the table and let the clinical trial labs actually field test it.

    What Mr. Levy is proposing is anti-science. It is the anathema of real science for biotech companies to forever hide their secret sauces and not let others test them.

    This exactly why patents are necessary.
    So that real science can take place on a transparent playing field.
    So we can “promote” the progress of science and the useful arts.

    (And by the way, use of false menu questions like the one in the title of this post are an example of manipulative “framing”. Yes you well know what framing is Mr. Levy.
    Why is the question one of choosing only A or only B? Why can’t the question can be: A or B or (A and B) or even a further choice C (e.g. public domain open source innovation)? Hmmm, do you think Roger Rabbit is being framed yet once again?)

    But with that said, please all of you posting here; be politically polite and do not openly challenge Mr. Levy’s models. –yes that’s more of my poking stick sarcasm. Of course I don’t mean it. Open criticism is part of open science.

  7. Anon April 20, 2017 1:46 pm

    …as to the title of this particular thread (and in view of step back’s comment), my mind recalls the Virtuous Circle, and I would answer the call of the question as: Yes, innovation leads to patents, AND patents lead to innovation.

    That is one reason why we should not be expecting a mere linear increase in patents over time, but rather, we should expect (and desire) MORE patents over time – at a geometric rate (or at least more than a steady state or linearly increasing rate).

    Does this place me in the “More Patent, All the Time, and Easier to Enforce” group?

    Damm straight it does.
    As would anyone who understands the dynamics of innovation also want to be in that group.

  8. Night Writer April 20, 2017 5:38 pm

    @6 step back: exactly.

    I can tell you for sure if Trade Secrets become the normal way to protect IP for high-tech, there is going to be a scream like you have never heard from the tech workers when they figure it what that means to their ability to move to other companies, disclose what they have done, and negotiate pay.

  9. H2H April 21, 2017 8:50 am

    Matt what do you think of all the district courts invalidating patents on eligibility grounds on pleadings motions? Do you think that’s what such motions are really for? Being fair, does it give you heartburn to think that might go away because it’ll suck the teeth out of the Alice analysis?

    What do you think of a different patent term for software patents at the application level? If you come up with a new and non obvious texting app (that’s also useful) you can get a patent, but it expires in 7 years. Software is developed fast, and quickly incorporated as “features” in later applications and so a different statutory scheme for applications might alleviate some of the problem.

  10. Anon April 21, 2017 9:31 am

    H2H,

    On what legal basis would you base your diminished patent reward?

    Why would you make such a distinguishment?

  11. Matt Levy April 21, 2017 10:27 am

    @9, @10

    I don’t think that a reduced patent term for software is either desirable or workable. If software is patentable, it’s patentable. There are all kinds of problems with trying to do what H2H is suggesting. For example, software that runs on an operating system might get 7 years, but an ASIC that did the same thing gets 20 years?

    Not to mention we have treaty obligations that could result in penalties for doing such a thing.

    Despite what critics seem to think, I don’t think of software as some lesser art that deserves less (or no) protection. My issues with patenting software have to do with the greater complication involved in writing clear, appropriately scoped software patents.

    On H2H’s other question, I think that there are real consequences to the trend of escalating discovery costs and the failure of many district courts to rein those in. Defendants want a resolution before discovery where possible, plaintiffs (at least NPE plaintiffs) tend to want to run up the defendants’ costs as quickly as possible in order to increase pressure to settle.

    These 101 motions on the pleadings are the defendants’ attempts at avoiding the cost of discovery.

    There are other ways to address the cost concerns. For example, I think it could be possible to phase a case in a way that front loads patent issues that don’t require extensive discovery, including much of invalidity. Patent owners have responded to such proposals, understandably, that they’re being disadvantaged by such phasing of a case. It’s a bit of a stand off.

    101 motions on the pleadings are the tool defendants have, and they’re going to use it unless a better tool comes along.

  12. Anon April 21, 2017 10:53 am

    The (patent) equivalency between the software and the ASIC is more telling than what most people who are against “software patents” are willing to admit to.

  13. H2H April 21, 2017 11:20 am

    @Anon: “statutory scheme” = new statute. Software application development cycles are short, and like Matt said, code gets reused and absorbed very quickly into many other applications especially if it is for “features” (e.g., “one-click”).

    I agree that treaty obligations have to be considered, but they are navigable and other countries seems to be able to have different classes of patent protection even based on subject matter. Firmware running on a micro-controller could go either way – it depends on the scheme the applicant elects and the scrutiny they are willing to have applied to their application.

    I agree 100% that software patent quality is abysmal and shameful. My gut tells me that a lot of those patents stemmed from drafters not comfortable or familiar with computer and software technology. For a time, a software application commanded twice the budget of an electrical or mechanical application, so anyone with a registration number was trying to do the work. Now that the prices are more in line with other technical fields that should stop.

    I don’t see motions to dismiss based on pleadings as an appropriate vehicle for invalidating patents. I don’t think it’s what those motions were intended to do. If my claim for contract damages is dismissed I can still bring my claim later unless there’s some kind of preclusion. If my patent is invalidated then, well, ouch!

    Summary judgment on eligibility can be done with some limited discovery and claim construction. I understand, though, if courts lose this procedure AND it’s cleared up that there are factual findings/questions of fact to consider then the Alice’s 101 analysis loses its teeth big time.

  14. step back April 21, 2017 11:56 am

    Matt @11

    Sir, you forgot to mention one other highly motivated party, the district court judge.

    Except for East Texas, most district court judges are not too pleased when a complex patent matter shows up on their docket.

    After all, they are used to spending their days hearing and understanding criminal cases not the esoteric jargon of patent lawyers.

    It is highly desirable not only for the defendant, but also for the adjudicator that the matter go away as easily and quickly as possible. Alice/Mayo is the judge’s hall pass out of the mess.

  15. Anon April 21, 2017 12:54 pm

    H2H,

    Your reply is a non-answer.

    So again, what is the legal basis for attempting to divide patent law (wherein no such division exists in patent law)?

    I “get” that your feelings and wants are there. I “get” that somehow you think that development cycle or integration matters (hint: it does not, leastwise from any legal standpoint).

    All your view comes down to, is an “I want.”

    Sorry, but that just won’t do.

  16. Anon April 21, 2017 12:55 pm

    Here is a hint, H2H: read the post at 10:53 AM.

  17. Night Writer April 22, 2017 8:42 am

    Matt Levy’s theories are just ridiculous. What we have is someone fabricating some model of the world that has no correspondence to reality. Then he goes around and argues that his model of how patents work is real. Just absurd.

    I wonder if Matt Levy could pass a basic test of patents in the real world. My guess is no. That Matt Levy could not answer basic questions about how patents are used by start-ups, inventors, or corporations.

    So, why does some fabricated model of patents get any press? The reason is that it feeds into what companies like Google want to hear and likely serve as a calling card for Mr. Levy to attract business.

    You see I know a lot about this as you cannot be pro patent now without risking losing clients. And the opposite is true. The anti-patent judicial activist like Mr. Levy adopt the party line of the fabricated model of the world as a prerequisite of getting clients.

    Not sure how to fight these propagandists and sycophants in the face of so much money flowing into K street to burn patents down and the general ignorance of patents by the judiciary, President, and Congress.

  18. angry dude April 23, 2017 8:21 pm

    Take it from the trenches, dudes

    After I saw what happened to my *patented* innovation I lost any incentive whatsoever to innovate again and will be sure to tell any prospective *innovators* to rethink their positions…

    “Fool me once – shame on you, fool me twice – shame on me”

  19. angry dude April 23, 2017 9:05 pm

    Perhaps Matt should have a tattoo on his forehead:

    “Software = Hardware. Period.”

    I can recommend good tattoo artist

  20. angry dude April 23, 2017 9:17 pm

    Matt Levy @11

    Dude, do you have any idea about the subject ???

    “Discovery costs” for software products ???

    How bout zero, zilch, none

    Just pass full source code base used for current product build and let plaintiffs attorneys and the court sort it out…

    Don’t like it ?

    Then let your own attorneys milk you for 500K or more

    Useless, just useless

  21. angry dude April 23, 2017 9:30 pm

    A patent integrity test for Matt:

    C = M^e (mod n)
    M = C^d (mod n)

    (from RSA patent)

    And you can do it entirely in your head (for small numbers, of course)

    And it can be done (and WAS done zillion times) in software, firmware, hardware, wetware, t-shirt ware .. you name it ware…

    So… yes or no, Matt ???

  22. step back April 24, 2017 10:40 am

    angry,

    Time to move on.
    Both Elvis and Matt have left the building.

    https://patentu.blogspot.com/2017/04/trade-secrecy-versus-progress-of.html